NVE Corporation 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for NVE Corporation for the period ended June 30, 2007. NVE develops and sells spintronic devices, including sensors and couplers, utilizing nanotechnology that relies on electron spin. The company also licenses MRAM technology.
Key Financial Metrics
| Metric | Q1 FY2008 (Ended June 30, 2007) | Q1 FY2007 (Ended June 30, 2006) |
|---|---|---|
| Total Revenue | $4,709,283 | $3,635,195 |
| Gross Profit | $3,266,315 | $2,235,374 |
| Gross Margin | 69.4% | 61.5% |
| Net Income | $1,587,335 | $891,806 |
| Diluted EPS | $0.33 | $0.19 |
| Operating Cash Flow | $1,876,904 | $591,598 |
| Cash & Marketable Securities | $19,830,635 | $18,289,191 (as of Mar 31, 2007) |
| Total Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 29.5% year-over-year. Product sales rose 39.8% due to higher sales of spintronic sensors and couplers, partially offset by a 24.3% decline in contract research and development revenue due to reduced U.S. Government contract awards.
- Margin Expansion: Gross profit margin improved to 69.4% from 61.5%, driven by a more profitable revenue mix and higher margins on product sales.
- Expense Trends: R&D expenses decreased 4% due to project completions. Selling, general, and administrative (SG&A) expenses increased 39% primarily due to higher legal fees and audit/Sarbanes-Oxley compliance costs.
- Interest Income: Net interest income more than doubled (101.7% increase) to $224,521, attributed to higher interest rates and an increased portfolio of interest-bearing securities.
Outlook, Risks, and Contingencies
- Tax Outlook: Management expects to begin paying regular cash income taxes in the second quarter of fiscal 2008 as stock-based compensation deductions and tax credits are fully utilized. This will substantially increase cash tax payments.
- Legal Proceedings: A consolidated class-action lawsuit regarding alleged misrepresentations was dismissed with prejudice on July 3, 2007. However, plaintiffs may appeal, and related derivative actions remain pending. No liability has been recorded, but legal expenses are expected to continue.
- Customer Concentration Risk: The agreement with Agilent Technologies expired on June 26, 2007. While Avago Technologies (successor to Agilent's relevant division) continues to order products, there is no assurance of continued distribution. The agreement with St. Jude Medical expires December 31, 2007, with renewal terms uncertain.
- Liquidity: The company maintains a strong liquidity position with approximately $19.8 million in cash and marketable securities, deemed adequate for the next 12 months.
Investor Verification Checklist
- Verify the status of the pending derivative lawsuits and potential appeal of the class-action dismissal.
- Confirm the renewal status of the St. Jude Medical agreement and the continuity of orders from Avago Technologies post-Agilent contract expiration.
- Monitor cash flow statements in the next quarter to confirm the onset of regular cash income tax payments.
- Review the composition of the $18.9 million marketable securities portfolio for interest rate sensitivity and unrealized losses.